In alternative embodiments, the invention provides a "triple combination" therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor； and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn's Disease and complications of Crohn's Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti - TNFα composition, or a composition capable of down-modulating TNFα activity； (2) a Hyperbaric Oxygen Treatment, or HBOT； and (3) an anti- Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.Cette invention concerne, dans certains modes de réalisation, une trithérapie permettant de traiter, améliorer et prévenir la maladie de Crohn (ou syndrome de Crohn, iléite terminale ou distale ou entérite régionale) ou des troubles et pathologies associées chez le mammifère, par exemple la paratuberculose (ou maladie de Johne), y compris des troubles chroniques et à prédisposition génétique, dans lesquels la flore microbienne ou bactérienne de l'intestin est au moins un facteur causatif ou symptomatique ； et des compositions permettant de l'appliquer. Dans d'autres mod
